On Monday, Shares of Oracle Corporation (NYSE:ORCL), lost -1.26% to $38.51.
To provide sales teams with the modern processes, tools, resources and intelligence required to enhance revenue, Oracle (NYSE: ORCL) recently declared noteworthy updates to the Oracle Sales Cloud. Part of Oracle Applications Cloud Release 10, the latest release of Oracle Sales Cloud assists organizations enhance sales and drive efficiencies through a simplified user experience that delivers improved analytics, partner relationship administration and industry-specific solutions.
The way customers interact with an organization’s sales department is rapidly changing. A recent study by CEB found that 57 percent of the purchasing process is over before customers even talk to an organization’s sales team. In this new business environment, organizations need to empower their sales teams with fast, easy and modern sales tools that support mobile productivity, insightful and collaborative selling, and aggressive pipeline creation.
With the latest release of Oracle Sales Cloud, Oracle assists sales teams enhance business agility through improved decision-making and collaboration. A modern, interactive dashboard comprises new pre-built reports and improved visualizations that provide the sales team with insights and analysis in real time. In addition, sales professionals can take advantage of a new Mobile App Designer tool to create intuitive reports and dashboards using drag and drop functionality, specifically designed for smartphones and tablets. To further enhance the sales process, Oracle Sales Cloud now enables partners and sales teams to communicate securely in the Oracle Social Network. Robust reporting capabilities have also been added to Oracle Sales Cloud partner relationship administration capabilities to enable improved real-time analysis.
Oracle Corporation develops, manufactures, markets, sells, hosts, and supports database and middleware software, application software, cloud infrastructure, hardware systems, and related services worldwide.
Shares of Brocade Communications Systems, Inc. (NASDAQ:BRCD), declined -1.09% to $9.96, during its last trading session.
Brocade Communications Systems declared a partnership with CERN openlab to assist the world’s largest and most respected center for scientific research develop a long-term software-defined networking (SDN) strategy for the New IP. Brocade has been named an official networking contributor member to CERN openlab, building on its previous relationship as a technology supplier to CERN.
Created in 2001, CERN openlab is a unique public-private partnership between CERN and leading ICT companies from across the world. Its mission is to accelerate the development of cutting-edge solutions to be used by the worldwide Large Hadron Collider (LHC) community.
Brocade will be collaborating with CERN openlab on a new solution designed to assist the organization address the long-term challenges facing its network infrastructure. Due to the nature of the research carried out by CERN, the organization generates extremely large data volumes and therefore needs an efficient, scalable, and flexible network in order to handle traffic spikes. The project with Brocade is intended to create a future-proof network based on the New IP and featuring a framework of SDN applications to optimize the routing of data traffic entering and leaving the organization. Brocade will also create improved user interfaces for its solutions, giving collaborators at CERN the ability to view graphical charts and visualizations showing real-time and historical traffic information.
Brocade Communications Systems, Inc. provides storage area networking (SAN) and Internet protocol networking solutions for businesses and organizations worldwide. It operates through SAN Products, IP Networking Products, and Global Services segments.
Finally, Laboratory Corp. of America Holdings (NYSE:LH), ended its last trade with -0.38% loss, and closed at $121.71.
Laboratory Corporation of America Holdings declared that Covance Drug Development has relocated its clinical research unit (CRU) in Dallas, TX, to a new, fit-for-purpose clinical research facility. The new unit, which opened earlier this month, has expanded from 72 to 100 medical beds and is located in the same building as the preceding unit. In addition, a LabCorp patient service center will be co-located in the CRU, at which patients will have an opportunity to learn more about volunteering and participating in early stage clinical trials.
With more than 55,000 square feet of space, the new CRU comprises a cGMP pharmacy, dedicated ophthalmology procedure rooms, an advanced telemetry system, and a glucose clamp suite, in addition to dedicated screening and outpatient visit areas. The pharmacy comprises three sterile and two non-sterile manufacturing suites, which allows the site to meet current Good Manufacturing Practices. The telemetry system enables the team to perform continuous, high-quality data monitoring, supporting improved monitoring of study participants and quick adjustments to treatment regimens, when necessary.
The Dallas clinic employs about 75 medical and professional staff with plans to expand to 120 employees.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. The company offers a range of clinical laboratory tests and procedures, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, STD tests, HCV tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
